China Biotech Weekly #2: 15 Law Firms Published BIOSECURE Advisories — Here's What They Agree On (and Where They Diverge)

This Week's Top Takeaway

Within three weeks of the BIOSECURE Act's enactment, at least 15 Am Law 100 firms have published client advisories. The consensus: BGI is a near-certain BCC; WuXi's status depends on DoD's 1260H list update and OMB's Category B review; the grant restriction catches more organizations than most expect; and the implementation timeline leaves less room than it appears. Where firms diverge: the likelihood of WuXi 1260H listing, the breadth of "biotechnology equipment or services," and whether the 5-year grandfathering period provides meaningful protection.

Where Firms Diverge

WuXi 1260H probability: Ropes & Gray and Goodwin Procter appear to assign higher probability to WuXi 1260H listing; Baker McKenzie and Arnold & Porter take a more cautious "wait and see" posture. The divergence reflects genuine uncertainty about whether DoD will act on the congressional recommendation. Scope of "biotechnology": K&L Gates provides the most expansive reading of the "biotechnology equipment or services" definition, arguing it could capture software tools and data analytics platforms. Others construe it more narrowly toward physical equipment and direct manufacturing services. Grandfathering adequacy: Latham & Watkins emphasizes that the 5-year grandfathering period provides a meaningful transition runway. Morrison Foerster notes that the grandfathering is unavailable for 1260H-listed companies (i.e., BGI), creating a two-tier compliance timeline.

BIOSECURE Watch

Status: 🟡 New Development

Multiple law firm advisories published (see above)
Congressional 1260H letter to DoD remains the key WuXi risk indicator
No OMB guidance or rulemaking activity yet — expected to begin Q2 2026
SEC risk factor disclosures starting: 3 public companies have added BIOSECURE language to 10-K filings in the first week of January

Takeaways for BD Teams

Read at least one full advisory. Baker McKenzie's is the most comprehensive; K&L Gates has the most practical compliance checklist; Ropes & Gray provides the best WuXi risk assessment. All are publicly available.

The grant restriction is the hidden risk. If you or your partners receive any federal funding, your BIOSECURE exposure extends to every service provider in the funded workflow. Map this now.

"Wait for the BCC list" is not a compliance strategy. Every firm recommends starting assessments immediately. The firms diverge on urgency but none recommend waiting.

Track the 1260H list update. If WuXi is added to the 1260H list, the compliance timeline accelerates dramatically — no grandfathering period, and restrictions begin 60 days after FAR revision.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan